Trevi Therapeutics priced an underwritten public offering of 11.6 million shares at $13.00 per share, raising approximately $150 million before underwriting costs. The clinical-stage biopharmaceutical company is developing Haduvio (oral nalbuphine ER) for treating chronic cough in patients with idiopathic pulmonary fibrosis and other lung conditions. The offering is expected to close on April 20, 2026.

Trevi Therapeutics priced an underwritten public offering of 11.6 million shares at $13.00 per share, raising approximately $150 million before fees. The clinical-stage biopharmaceutical company is developing Haduvio (oral nalbuphine ER) for chronic cough treatment in IPF, non-IPF ILD, and refractory chronic cough patients. The offering is expected to close on April 20, 2026.

The chronic refractory cough market is projected to expand by 2034, driven by rising patient diagnoses, improved awareness, and emerging therapies targeting refractory cough conditions.

Law firm Kaskela Law LLC is investigating Trevi Therapeutics for potential securities law violations or breaches of fiduciary duties, encouraging long-term investors to contact them for more information.

The pulmonary fibrosis market is driven by the increasing prevalence of the disease, especially idiopathic pulmonary fibrosis, among the aging population. Innovations in drug development and diagnostics, favorable reimbursement policies, and greater awareness are fueling market growth. The pipeline appears robust with over 110 active players working on 120+ pipeline drugs.

Trevi Therapeutics (TRVI) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Trevi Therapeutics (TRVI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Trevi Therapeutics, Inc. (TRVI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

A more selective small-cap index has consistently outperformed the Russell 2000

Trevi Therapeutics, Inc. (TRVI) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

The heavy selling pressure might have exhausted for Trevi Therapeutics, Inc. (TRVI) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Trevi Therapeutics, Inc. (TRVI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.